FTC Says Noerr Doesn't Shield AndroGel Pay-For-Delay Deal
The Federal Trade Commission on Tuesday told a Georgia federal court that two generic drug companies did not satisfy the high burden necessary to appeal a ruling that Noerr-Pennington antitrust immunity...To view the full article, register now.
Already a subscriber? Click here to view full article